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Abstract: Heme oxygenase-1 (HO-1) is an enzyme contributing to the development and progression
of different cancer types. HO-1 plays a role in pathological angiogenesis in bladder cancer and
contributes to the resistance of this cancer to therapy. It also regulates the expression of microRNAs
in rhabdomyosarcoma and non-small cell lung cancer. The expression of HO-1 may be regulated by
hypoxia inducible factors (HIFs) and Nrf2 transcription factor. The expression of HO-1 has not so
far been examined in relation to Nrf2, HIF-1α, and potential mediators of angiogenesis in human
bladder cancer. We measured the concentration of proinflammatory and proangiogenic cytokines
and the expression of cytoprotective and proangiogenic mRNAs and miRNAs in healthy subjects
and patients with bladder cancer. HO-1 expression was upregulated together with HIF-1α, HIF-2α,
and Nrf2 in bladder cancer in comparison to healthy tissue. VEGF was elevated both at mRNA and
protein level in the tumor and in sera, respectively. Additionally, IL-6 and IL-8 were increased in sera
of patients affected with urothelial bladder cancer. Moreover, miR-155 was downregulated whereas
miR-200c was elevated in cancer biopsies in comparison to healthy tissue. The results indicate that
the increased expression of HO-1 in bladder cancer is paralleled by changes in the expression of other
potentially interacting genes, like Nrf2, HIF-1α, HIF-2α, IL-6, IL-8, and VEGF. Further studies are
necessary to also elucidate the potential links with miR-155 and miR-200c.
Keywords: bladder cancer; urothelial cancer; heme oxygenase-1; hypoxia inducible factor; Nrf2;
miR-155; miR-200c; VEGF; angiogenesis
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1. Introduction
Bladder cancer (urothelial cancer) is the 7th most common cancer in men and 17th in women, and
is more frequent in well-developed regions, where 60% of all incidents occur. Non-muscle-invasive
bladder cancer is characterized by a high rate of recurrence—despite the total resection of the tumor
it reappears in 75% of patients. The five-year survival rate is around 57% [1,2]. The major cause of
development of bladder cancer is long-term exposure to environmental risk factors. The primary
culprits are smoking, chemical compounds binding DNA (like aromatic amines), or arsenic (the
metabolism of which is associated with the generation of reactive oxygen species) [2]. Recent data
indicate the role of oxidative stress in the progression of bladder cancer [3].
Among transcription factors affected by oxidative stress, and which are altered in bladder cancer,
are hypoxia inducible factors (HIF-1α, HIF-2α), and Nrf2 transcription factor [3]. In response to
oxidative stress, Nrf2 binds to promoters of genes encoding antioxidative enzymes [4]. It is believed
to be a mediator of action of chemopreventive compounds [5–8], and it also contributes to resistance
to cisplatin [9] and photodynamic therapy [10]. HIF-1α and HIF-2α, which regulate cellular redox
homeostasis, are factors inducing angiogenesis and inflammatory reaction [11,12]. They are correlated
with increasing invasiveness, macrophage infiltration, and angiogenesis in bladder cancer [13–15].
Among the direct mediators of HIFs in bladder cancer, vascular endothelial growth factor (VEGF)
is usually listed [13,15–17]. Its expression correlates with enhanced angiogenesis, proliferation, and
metastatic potential in urothelial tumors [18–20]. However, since clinical trials based on VEGF-targeted
anti-angiogenic therapies of bladder cancer have not given satisfactory results [21], there is a need to
search for other mediators of both pro-angiogenic and anti-cytotoxic effects of HIFs and Nrf2.
Heme oxygenase-1 (HO-1) is a heme-degrading enzyme of known pro-angiogenic and
cytoprotective effects, the expression of which may be induced by both Nrf2 and HIF-1α [22]. Moreover,
HO-1 has a potent impact on the development of different types of cancer [23]. In recent years,
an increasing body of evidence points to the role of HO-1 in pathological angiogenesis in bladder
cancer [24] and in some cases in the resistance of this cancer to chemo- and radiotherapy [10,25,26].
However, only a few of the studies analyzed clinical material from patients affected by bladder cancer,
confirming a positive correlation of HO-1 level with the proliferation of cancer cells, VEGF-induced
angiogenesis, and, finally, the malignant behavior of the cancer [24,27–29], whereas none of them
involved comparison to the healthy tissue. Furthermore, the expression of HO-1 was never assessed
together with Nrf2 in the clinical samples and only one study showed the analysis of HO-1 with
HIF-1α and HIF-2α in urothelial tumors, suggesting the correlation between their expressions [24].
HO-1 is known to potently regulate the expression of miRNAs in muscle myoblasts and
rhabdomyosarcoma [30–32]. The expression of miRNAs is also changed in bladder cancer, which
may be a diagnostic parameter [33,34]. Changes in miR-200c are suggested to be associated with
the pathogenesis of bladder cancer and to affect the efficacy of therapeutic treatment [35,36]. Similar
tendencies were demonstrated for other types of cancer [37,38], but the current data for bladder cancer
are ambiguous and show either an induction of miR-200c expression [39–41] or an inhibition [33,42–45].
On the other hand, miR-133b [46–48] and miR-133a [39,46,49–52], shown by us to be strongly affected
by HO-1 [30], are also downregulated in bladder cancer.
The aim of this study was to analyze the level of proinflammatory and proangiogenic cytokines
in the sera and determine the expression of genes associated with cytoprotection and angiogenesis




Patients with known bladder cancer in stages Ta, Tis, or T1 and patients with suspected bladder
cancer were recruited (N = 21; age 51–80, mean age = 67; five females and 16 males). Two hours prior
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to the TURBT (transurethral resection of the bladder tumor) procedure, patients underwent bladder
instillation with 50 mL of 8 mM solution of HAL (hexyl aminolevulinate) hydrochloride in phosphate
buffered saline (Hexvix, Photocure) through a Foley catheter. After the HAL solution was evacuated,
the bladder was inspected by white light cystoscopy. Lesions or suspicious areas were classified and
mapped onto a bladder chart in blue. The bladder was then inspected by HAL fluorescence cystoscopy.
Lesions or suspicious areas were classified and mapped onto the bladder chart in red. Fluorescence
cystoscopy was a supplementary but not substitutional procedure. The diameter of the lesions or
suspicious areas were 0.2–2 cm, while the majority did not exceed 1 cm. Biopsies (0.1–0.3 cm diameter)
were taken from all mapped areas. Test materials were collected for histopathological analysis and
some of them were used for the isolation of RNA. Among 27 samples collected for mRNA and miRNA
analysis, papillary urothelial neoplasm of low malignant potential, according to the International
Society of Urological Pathology guidelines [53], was diagnosed in two cases, low-grade urothelial
carcinoma in 13, and high-grade urothelial carcinoma in one (out of the initial group of 21 patients,
bladder cancer was diagnosed in N = 16 cases; age 51–80, mean age 67; five females and 11 males).
Eleven samples for mRNA and miRNA analysis were histologically assessed as unaltered, healthy
tissue—N = 11, age 57–74, mean age 67; two females and nine males. Those 11 samples were derived
from patients finally diagnosed as healthy (N = 5, age 58–73, mean age 69; 5 males) and 6 samples of
healthy tissue were also found among patients who had bladder cancer confirmed in another area.
Serum was collected for the analysis of cytokines from all patients subjected to cystoscopy (16
patients with subsequently diagnosed bladder cancer and five assessed histopathologically as healthy)
as well as from additional healthy, voluntary, age-matched controls (the total number of healthy
controls included for the measurement of cytokine: N = 9, age 51–73, mean age = 65; three females and
six males).
The research was completed in September 2012; it complied with the Declaration of Helsinki
and was approved by the Local Bioethical Commission (agreement No. KBET/197/B/2012). Patients
provided written informed consent for the study.
2.2. RNA Isolation and qRT-PCR
RNA isolation followed by reverse transcription and quantitative PCR for genes and miRNA
were performed with standard procedures, described elsewhere [30]. Primers used in qRT-PCR are
presented in Tables 1 and 2.
Table 1. Sequences of starters for genes.
Gene Sequence of Starters
EF2
forward 51-GAC ATC ACC AAG GGT GTG CAG-31
reverse 51-TCA GCA CAC TGG CAT AGA GGC-31
HO-1
forward 51-GTG GAG MCG CTT YAC RTA GYG C-31
reverse 51-CTT TCA GAA GGG YCA GGT GWC C-31
VEGF
forward 51-ATG CGG ATC AAA CCT CAC CAA GGC-31
reverse 51-TTA ACT CAA GCT GCC TCG CCT TGC-31
Nrf2
forward 51-GGG GTA AGA ATA AAG TGG CTG CTC-31
reverse 51-ACA TTG CCA TCT CTT GTT TGC TG-31
HIF-1α
forward 51-TGC TTG GTG CTG ATT TGT GA-31
reverse 51-GGT CAG ATG ATC AGA GTC CA-31
HIF-2α
forward 51-TCC GAG CAG TGG AGT CAT TCA-31
reverse 51-GTC CAA ATG TGC CGT GTG AAA-31
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Table 2. Sequences of starters for miRNA.
miRNA Sequence Of Specific Starters
U6 51-CGC AAG GAT GAC ACG CAA ATT C-31
miRNA-133a 51-TTG GTC CCC TTC AAC CAG CTG T-31
miRNA-155 51-TTA ATG CTA ATT GTG ATA GGG GT-31
miRNA-200c 51-TAA TAC TGC CGG GTA ATG ATG GA-31
2.3. Luminex Analysis of Cytokine and Growth Factor Concentrations in Plasma
Concentrations of interferon-γ (IFN-γ), interleukin (IL)-1β, IL-6, IL-8, IL-10, IL-12, IL-17,
monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-α (TNFα), and VEGF in plasma
were evaluated using Milliplex FlexMap 3D (Millipore, Billerica, MA, USA) according to the
vendor’s protocol.
2.4. Statistical Analysis
The normal distribution of data was checked using the D’Agostino–Pearson test. Statistical
significance was assessed using the Student’s t-test or Welch’s Mann–Whitney U-test, and accepted at
p < 0.05. Correlation was analyzed using Spearman’s rank correlation.
3. Results
3.1. Level of Cytokine in the Sera
The analysis of cytokine levels was performed in the sera of patients with diagnosed bladder
cancer (N = 16) and aged-matched healthy controls (N = 9). IL-6 was significantly increased in the
material collected from patients affected by bladder cancer, whereas TNFα showed a tendency to
be induced (p = 0.08) (Figure 1). Proangiogenic VEGF and IL-8 were both significantly increased in
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Figure 1. Concentrations of i the serum of patients with diagnosed bladder ancer a d
in ealthy controls. Luminex, N = 9–16; each dot repre ents one individual, lin represents a mean;
* p < 0.05; ** p < 0.01.
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3.2. Expression of Proangiogenic and Cytoprotective Genes in Tumor Samples
The analysis of gene expressions at mRNA level revealed that Nrf2 (a transcription factor and
regulator of the expression of proteins that are a second line of cell defense against oxidative stress), and
its downstream target HO-1, were upregulated in samples of bladder cancer (N = 16) in comparison to
healthy tissue (N = 11) (Figure 2). Similarly, factors regulated by hypoxia (HIF-1α and HIF-2α) and















bladder  cancer, whereas miR‐155  is  downregulated. No  changes were  observed  in  the  case  of 
miR‐133a (Figure 3). 
Figure 2. Gene expression at mRNA level in samples of bladder cancer and in healthy tissue. qRT-PCR,
N = 11–16; each dot represents one individual, line represents a mean; * p < 0.05; ** p < 0.01; *** p < 0.001.
3.3. Analysis of miRNA Expression in Cancer Samples
Analysis of miRNAs showed that the level of miR-200c is significantly induced in samples of
bladder cancer, whereas miR-155 is downregulated. No changes were observed in the case of miR-133a
(Figure 3).
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and  the  expression  of  genes  analyzed.  MiR‐200c  was  found  to  positively  correlate  to  VEGF 
expression in bladder cancer (Table 3). 
Table3. Spearman’s rank correlation of tested miRNA/mRNA; * p < 0.05. 
  HO‐1  Nrf2  VEGF  HIF1  HIF2 
miR‐133a  −0.329  −0.347  0.161  0.063  0.109 
miR‐155  0.194  −0.151  −0.009  0.411  −0.385 
miR‐200c  0.259  0.406  0.606 *  0.365  0.424 
4. Discussion 
Our results confirm previous data showing the increased production of proinflammatory and 




reduced survival of patients with bladder cancer  [58]. TNFα was also detected  in  the sera and  in 
peripheral blood mononuclear cells of patients with bladder cancer, although no correlation with 
Figure 3. The expression of selected miRNAs in samples of bladder cancer and in healthy tissue.
qRT-PCR, N = 11–16; each dot represents one individual, line represents a mean; * p < 0.05; *** p < 0.001.
Spearman’s rank correlation coefficient was used to determine the correlation between miRNAs
and the expression of genes analyzed. MiR-200c was found to positively correlate to VEGF expression
in bladder c cer (Table 3).
Table 3. Spearman’s rank correlation of tested miRNA/mRNA; * p < 0.05.
HO-1 Nrf2 VEGF HIF1 HIF2
miR-133a ´0.329 ´0.347 0.161 0.063 0.109
miR-155 0.194 ´0.151 ´0.009 0.411 ´0.385
miR-200c 0.259 0.406 0.606 * 0.365 0.424
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4. Discussion
Our results confirm previous data showing the increased production of proinflammatory and
proangiogenic cytokines in patients affected by bladder cancer, and suggesting their diagnostic
importance [20,54–56].
Upregulation of IL-6 was detected in the sera and urine of bladder cancer patients [56,57], as well
as in tumors [58,59]. IL-6 was correlated with higher clinical stage, higher recurrence rate, and reduced
survival of patients with bladder cancer [58]. TNFα was also detected in the sera and in peripheral
blood mononuclear cells of patients with bladder cancer, although no correlation with tumor stages
was shown [59,60]. Our results confirm a significantly enhanced level of IL-6 and only a tendency
toward such an induction in the case of TNFα.
IL-8 was shown to induce both angiogenesis and tumorigenecity, and in this way it can enhance
the metastatic potential of bladder cancer [18–20,55,61]. A similar relationship was demonstrated for
VEGF expression, which enhances angiogenesis, proliferation, and metastatic potential in urothelial
tumors [18–20]. Accordingly, we observed the induction of IL-8 (at protein level in sera) and VEGF (at
protein level in sera and at mRNA level in the specimen of urothelial bladder cancer).
The upregulation of VEGF correlates to HIF-1α expression. We have also showed for the first time
the elevated expression of both Nrf2 and HO-1 in urothelial bladder cancer. However, both Nrf2 and
HIFs transcription factors are mostly regulated at protein stability [12,62], though its mRNA increase
also indicates possible protein upregulation. It is therefore possible that Nrf2, a known inducer of
HO-1 expression in different tissues [22], is also responsible for elevating HO-1 expression in bladder
cancer. This supports previous in vitro data suggesting that Nrf2 may be associated with the enhanced
expression of HO-1 in bladder cancer cells [10], which in turn enhances pathological angiogenesis in
tumors and the viability of cells during therapy [10,24–26].
The mechanism of proangiogenic, and especially cytoprotective properties of HO-1 in bladder
cancer is not well understood. It is associated with increased VEGF, HIF-1α, and HIF-2α [24]. Taking
into account that HO-1 also potentiates the expression of other proangiogenic factors [22,63], and
that our results show increased IL-8 in the sera of bladder cancer patients, the involvement of other
mediators is also possible. HO-1 regulates the cell cycle via the modulation of soluble guanylyl cyclase
activity, p38-signalling pathway, or PI3K pathway, which are activated by one of the heme degradation
end products, carbon monoxide (CO) [22]. It is therefore possible that these mechanisms might also
play a role in bladder cancer. Moreover, in other studies the HO-1 level was shown to correlate with the
expression of cyclooxygenase-2 (COX-2) both in vivo (in samples of bladder cancer patients [28]) and
in vitro (in bladder cancer cell lines cultured in hypoxic conditions [24]). COX-2 is a factor associated
with carcinogenesis and higher pathological stages of bladder cancer [64]. It requires further analysis
to examine the possible link between HO-1 and COX-2 in bladder cancer.
Furthermore, HO-1 is a potent regulator of miRNAs [30], inhibiting among others miR-133a,
miR-133b, and miR-1 [30]. The importance of these miRNAs has been suggested in bladder
cancer [46–52,65,66]. However, our analysis does not show the changes in the expression of miR-133a.
In turn, we have observed a decreased expression of miR-155, which was previously shown to be
increased in the urine of the patients affected by urothelial bladder cancer [33]. Accordingly, the results
showed that miR-155 is upregulated in urothelial tumors and associated with poor survival [67] as
well as with the induction of the proliferation of bladder cancer cell line in vitro [68]. These results
seem contradictory to those presented here; however, it must be noted that the sequence of primers
used in that study [67] did not cover the mature miR-155-5p, which is detected in our analysis.
MiR-155 was shown to target HIF-1α in murine and human cells [69,70]; therefore, its downregulation
may be responsible for the upregulation of HIF-1α observed here in bladder cancer cells. Although
miR-155 was demonstrated to target HO-1 in rodent models [71,72] it must be noted that in human
cells it upregulates HO-1 expression by targeting Bach1—a repressor of HO-1 transcription [73].
Further studies are necessary to determine if there is any direct link between miR-155 and HO-1 in
bladder cancer.
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Finally, we have also demonstrated the increased expression of miR-200c in specimens of bladder
cancer in comparison to healthy controls, which supports previous data showing an upregulation
of this miRNA in bladder cancer [39–41]. As miR-200c has so far been shown to target HO-1 and
is associated with HO-1 decreased expression in other tissues and cancer types [74,75], we did not
expect that it could be a mediator of HO-1 upregulation or action in bladder cancer. On the other hand,
miR-200c was positively correlated with VEGF expression in samples of bladder cancer. Similarly,
miR-200c overexpression was shown to induce VEGF expression in non-small cell lung cancer [76],
although opposite results suggesting that miR-200c directly targets VEGF expression were also obtained
for different cancer types [38,77,78]. Therefore it seems that the relationship between miR-200c and
VEGF depends on cell type.
In conclusion, we have shown here for the first time that the expression of both HO-1 and Nrf2
is elevated in specimens of bladder cancer. Additionally, HIF-1α and HIF-2α are upregulated at the
mRNA level in urothelial bladder cancer and correlate with elevated VEGF expression in tumors and
with its increased concentration in the plasma of patients affected by bladder cancer in comparison
to healthy controls. The elevated level of proinflammatory and proangiogenic cytokines was also
observed in the sera of patients with bladder cancer. Among the miRNAs analyzed, upregulation of
miR-200c and downregulation of miR-155 were observed, which may be responsible for the induction
of HIF-1α mRNA. The expression of both HO-1 and Nrf2 is increased in bladder cancer compared to
healthy tissue.
Further studies with increased number of patients, and the functional assays for the potential
targets of microRNAs and transcription factors are necessary to validate the results described here.
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